Quantech prepares to launch cardiac test panel:
This article was originally published in Clinica
Quantech has submitted a 510(k) clearance application to the FDA for a test of the cardiac marker CK-MB. CK-MB is one of three human proteins that are considered to be definitive diagnostic markers for heart attack. The others are myoglobin - for which the company already sells a test - and troponin I. St Paul, Minnesota-based Quantech plans to launch a cardiac test panel for all three proteins for its DBx rapid diagnostic system. The system consists of a table-top instrument and disposable biosensers that use the company's Surface Plasmon Resonance (SPR) technology.
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.